Evogene (EVGN) Receivables - Other (2016 - 2025)

Evogene (EVGN) has disclosed Receivables - Other for 10 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Receivables - Other rose 2798.15% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, up 2798.15% year-over-year, with the annual reading at $1.6 million for FY2025, 2798.15% up from the prior year.
  • Receivables - Other hit $1.6 million in Q4 2025 for Evogene, up from $54000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $3.0 million in Q4 2023 to a low of $54000.0 in Q4 2024.
  • Historically, Receivables - Other has averaged $1.7 million across 5 years, with a median of $1.6 million in 2025.
  • Biggest five-year swings in Receivables - Other: plummeted 98.18% in 2024 and later skyrocketed 2798.15% in 2025.
  • Year by year, Receivables - Other stood at $2.7 million in 2021, then tumbled by 44.1% to $1.5 million in 2022, then soared by 100.61% to $3.0 million in 2023, then tumbled by 98.18% to $54000.0 in 2024, then surged by 2798.15% to $1.6 million in 2025.
  • Business Quant data shows Receivables - Other for EVGN at $1.6 million in Q4 2025, $54000.0 in Q4 2024, and $3.0 million in Q4 2023.